Skip to main content
Top
Published in: Immunity & Ageing 1/2021

Open Access 01-12-2021 | Editorial

Human endogenous retroviruses and ageing

Authors: Mikko Hurme, Graham Pawelec

Published in: Immunity & Ageing | Issue 1/2021

Login to get access

Excerpt

Over evolutionary time, the human genome has incorporated large amounts of genetic material from ancient retroviral infections, comprising ca. 8% of the total DNA. The majority of human endogenous retroviruses (HERVs) are defective due to the accumulation of mutations and deletions but some proviruses, especially in the youngest families (e.g. HERV-K (HML-2), contain intact genes permitting the production of proviral proteins (for a review, see [1]). The functions of HERVs have been under active investigation for decades and it is now known that far from being quiescent, some are involved in several crucial physiologic processes, clearly advantageous or essential to the host, e.g. placentation, neuroprotection and differentiation of cells in early embryos. However, there are now many publications also showing that HERVs are involved in the pathogenesis of several diseases (autoimmune, inflammatory, malignancies) [1]. …
Literature
1.
go back to reference Xue B, Sechi LA, Kelvin DJ. Human endogenous retrovirus K (HML-2) in health and disease. Front Microbiol. 2020;11:1–13.CrossRef Xue B, Sechi LA, Kelvin DJ. Human endogenous retrovirus K (HML-2) in health and disease. Front Microbiol. 2020;11:1–13.CrossRef
2.
go back to reference Mustelin T, Ukadike KC. How retroviruses and retrotransposons in our genome may contribute to autoimmunity in rheumatological conditions. Front Immunol. 2020;11:1–21.CrossRef Mustelin T, Ukadike KC. How retroviruses and retrotransposons in our genome may contribute to autoimmunity in rheumatological conditions. Front Immunol. 2020;11:1–21.CrossRef
Metadata
Title
Human endogenous retroviruses and ageing
Authors
Mikko Hurme
Graham Pawelec
Publication date
01-12-2021
Publisher
BioMed Central
Published in
Immunity & Ageing / Issue 1/2021
Electronic ISSN: 1742-4933
DOI
https://doi.org/10.1186/s12979-021-00228-x

Other articles of this Issue 1/2021

Immunity & Ageing 1/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine